Visual Function Benefit of Pegcetacoplan on a Prespecified Microperimetry Endpoint after 36 Months of Continuous Treatment from GALE (ASRS 2024 GA) - Apellis Medical Hub

Home / Congress Presentations / Geographic Atrophy / ASRS 2024

Visual Function Benefit of Pegcetacoplan on a Prespecified Microperimetry Endpoint after 36 Months of Continuous Treatment from GALE

Share Via Email

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.